Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful hard but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire job interview that I came away with a bad viewpoint of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, although the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology as well as connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) as well as the very first new drug application approval ($5 million), as well as royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it has this individual treatments as well as a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple delivering presentations and multiple publications.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this particular company. Judging with the multiples of thousands of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or even some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *